Explorer les evidences

601 casesIn Zimbabwe, there were 601 cholera cases and 23 deaths from November 2023 to July 2025.

Zimbabwecholéraobservé Nov 2023 – 31 July 2025Africa CDCdocument de 176 observations

79,6 %In Zimbabwe, point-of-care (POC) early infant diagnosis increased the percentage of HIV-infected infants initiated on treatment to 79.6%.

ZimbabweVIH/sidapublié 2020Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 13 observations

10,5 %In Zimbabwe, 10.5% of female sex workers testing HIV-positive through the outreach programme were classified as having recent HIV infection.

ZimbabweVIH/sidaobservé 2018publié 2020Journal of the International AIDS SocietyPubMeddocument de 4 observations

56 daysPoint-of-care (POC) early infant diagnosis reduced the time to antiretroviral therapy initiation by an average of 56.00 days in Zimbabwe.

ZimbabweVIH/sidapublié 2020Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 13 observations

11 %La prévalence de la neuropathie chez les personnes vivant avec le VIH en Ouganda et au Zimbabwe était de 11 % en 2014.

Ouganda · ZimbabweVIH/sidaobservé 2014HAL · Unilimdocument de 747 observations

For couples with an HIV-positive man on antiretroviral therapy, antiretroviral therapy with frequent viral load monitoring (ART/VL) was dominant—more effective and less costly than current practice.

ZimbabweVIH/sidaPubMeddocument de 8 observations

31 %In Zimbabwe, 31% of cholera cases were among children under 15 years old.

Zimbabwecholéraobservé Nov 2023 – 31 July 2025Africa CDCdocument de 176 observations

4,56 timesIn Zimbabwe, caregivers were 4.56 times more likely to receive early infant diagnosis (EID) results by 12 weeks of age with point-of-care (POC) versus laboratory-based EID.

ZimbabweVIH/sidapublié 2020Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 13 observations

4 942 USD/DALY_averterdFor HIV-discordant couples with an HIV-positive man not on antiretroviral therapy, ART/VL combined with PrEP was cost-effective at $4,942 per disability-adjusted life year (DALY) averted.

ZimbabweVIH/sidaPubMeddocument de 8 observations

815 USD/DALY_averterdFor HIV-discordant couples with an HIV-positive woman on antiretroviral therapy, ART/VL combined with vaginal insemination (VI) was highly cost-effective at $815 per disability-adjusted life year (DALY) averted.

ZimbabweVIH/sidaPubMeddocument de 8 observations

43,2 %In Zimbabwe, point-of-care (POC) early infant diagnosis increased the percentage of HIV-infected infants initiated on treatment from 43.2% to 79.6%.

ZimbabweVIH/sidapublié 2020Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 13 observations

For HIV-discordant couples with an HIV-positive woman on antiretroviral therapy, vaginal insemination (VI) was dominant.

ZimbabweVIH/sidaPubMeddocument de 8 observations

For HIV-discordant couples with an HIV-positive man not on antiretroviral therapy, oral pre-exposure prophylaxis (PrEP) for the HIV-negative partner was dominant.

ZimbabweVIH/sidaPubMeddocument de 8 observations

601 casesZimbabwe reported 601 cholera cases and 23 deaths, with the outbreak starting in November 2023.

Zimbabwecholéraobservé Nov 2023Africa CDCdocument de 176 observations

Over the past 20 years, incidence rates have stabilized among the younger age group in Uganda and Zimbabwe.

Ouganda · Zimbabwecancer (non précisé)observé past 20 yearspublié 2019International journal of cancereurope_pmcdocument de 6 observationsDOI 10.1002/ijc.31880

10,5 %Among female sex workers in Zimbabwe, 33 out of 313 testing HIV positive were classified as recently infected, representing 10.5%.

ZimbabweVIH/sidaobservé 2018publié 2021BMC health services researchPubMeddocument de 4 observations

4 702 USD/DALY_averterdFor couples with an HIV-positive man on antiretroviral therapy, ART/VL combined with oral pre-exposure prophylaxis (PrEP) was cost-effective at $4,702 per disability-adjusted life year (DALY) averted.

ZimbabweVIH/sidaPubMeddocument de 8 observations

4 425 confirmed_casesSince the beginning of 2025, 4,425 confirmed, 28,600 suspected, and 852 deaths (case fatality rate: 2.5%) of cholera were reported from six countries in the Southern Africa region: Angola, Malawi, Zambia, Zimbabwe, Mozambique.

Angola · Malawi · Mozambique · Zambie · Zimbabwecholéraobservé 2025Africa CDCdocument de 176 observations

62,37 daysPoint-of-care (POC) early infant diagnosis significantly reduced the time between sample collection and return of results to caregiver by an average of 62.37 days in Zimbabwe.

ZimbabweVIH/sidapublié 2020Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 13 observations

502 USD/DALY_averterdFor HIV-discordant couples with an HIV-positive man not on antiretroviral therapy, antiretroviral therapy with frequent viral load monitoring (ART/VL) was highly cost-effective at $502 per disability-adjusted life year (DALY) averted.

ZimbabweVIH/sidaPubMeddocument de 8 observations

40 000 personsThe Sickle Pan-African Research Consortium (SPARCo) registry includes data from over 40,000 persons living with sickle cell disease in seven African countries.

Ghana · Mali · Nigeria · Ouganda · Tanzanie · Zambie · Zimbabwedrépanocytosepublié 2026Database : the journal of biological databases and curationeurope_pmc

1 000 USD/DALY_averterdFor HIV-discordant couples with an HIV-positive woman not on antiretroviral therapy, ART(routineVL)+VI, ART/VL, and ART/VL+VI were highly cost-effective (<$1,000 per disability-adjusted life year (DALY) averted).

ZimbabweVIH/sidaPubMeddocument de 8 observations

23 deathsZimbabwe reported 23 cholera deaths, with the outbreak starting in November 2023.

Zimbabwecholéraobservé Nov 2023Africa CDCdocument de 176 observations

2 confirmed_casesZimbabwe reported 2 confirmed mpox cases and zero deaths among confirmed cases in 2024.

Zimbabwempoxobservé 2024Africa CDCdocument de 74 observations

Over the past 20 years, incidence rates among older adults have increased in both sexes in Uganda and Zimbabwe.

Ouganda · Zimbabwecancer (non précisé)observé past 20 yearspublié 2019International journal of cancereurope_pmcdocument de 6 observationsDOI 10.1002/ijc.31880